Published in Biochemistry on November 07, 2006
The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev (2008) 2.06
Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J Neurooncol (2007) 1.50
Abnormality of pl6/p38MAPK/p53/Wipl pathway in papillary thyroid cancer. Gland Surg (2012) 1.40
Targeting protein serine/threonine phosphatases for drug development. Mol Pharmacol (2009) 1.25
Sequential activation and deactivation of protein function using spectrally differentiated caged phosphoamino acids. J Am Chem Soc (2011) 1.09
Discovery of small molecule inhibitors of the PH domain leucine-rich repeat protein phosphatase (PHLPP) by chemical and virtual screening. J Med Chem (2010) 0.99
Negative regulation of multifunctional Ca2+/calmodulin-dependent protein kinases: physiological and pharmacological significance of protein phosphatases. Br J Pharmacol (2008) 0.92
Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3. Oncotarget (2016) 0.89
Optimization of a cyclic peptide inhibitor of Ser/Thr phosphatase PPM1D (Wip1). Biochemistry (2011) 0.89
Retinoblastoma loss modulates DNA damage response favoring tumor progression. PLoS One (2008) 0.88
A small molecular scaffold for selective inhibition of Wip1 phosphatase. ChemMedChem (2008) 0.81
Viewing serine/threonine protein phosphatases through the eyes of drug designers. FEBS J (2013) 0.81
Design and NMR studies of cyclic peptides targeting the N-terminal domain of the protein tyrosine phosphatase YopH. Chem Biol Drug Des (2010) 0.79
Absence of Wip1 partially rescues Atm deficiency phenotypes in mice. Oncogene (2011) 0.78
Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis. Sci Rep (2016) 0.75
Structurally diverse low molecular weight activators of the mammalian pre-mRNA 3' cleavage reaction. Bioorg Med Chem (2013) 0.75
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A (2003) 9.14
p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol (2004) 5.82
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell (2008) 5.11
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet (2004) 3.89
Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell (2007) 3.68
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol (2002) 3.55
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J (2002) 3.45
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J (2002) 3.29
Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab (2005) 3.15
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res (2008) 2.45
Studying multisite binary and ternary protein interactions by global analysis of isothermal titration calorimetry data in SEDPHAT: application to adaptor protein complexes in cell signaling. Protein Sci (2007) 2.44
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res (2003) 2.40
Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell (2006) 2.39
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A (2003) 2.38
Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol (2009) 2.34
Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol (2005) 2.31
Oligomerization of signaling complexes by the multipoint binding of GRB2 to both LAT and SOS1. Nat Struct Mol Biol (2006) 2.10
Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle (2003) 2.10
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem (2003) 2.02
Distinct p53 genomic binding patterns in normal and cancer-derived human cells. Cell Cycle (2011) 2.01
A conserved mechanism for centromeric nucleosome recognition by centromere protein CENP-C. Science (2013) 2.00
Structural basis for recognition of centromere histone variant CenH3 by the chaperone Scm3. Nature (2011) 1.99
A correlation between TCR Valpha docking on MHC and CD8 dependence: implications for T cell selection. Immunity (2003) 1.95
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell (2008) 1.91
Protein folding: defining a "standard" set of experimental conditions and a preliminary kinetic data set of two-state proteins. Protein Sci (2005) 1.91
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol (2009) 1.84
Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol Cell (2006) 1.82
A protein folding pathway with multiple folding intermediates at atomic resolution. Proc Natl Acad Sci U S A (2005) 1.82
Membrane fusion. Chem Rev (2003) 1.69
Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol (2002) 1.65
Chz1, a nuclear chaperone for histone H2AZ. Mol Cell (2007) 1.64
Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem (2003) 1.63
Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes. J Proteome Res (2006) 1.63
Relating molecular flexibility to function: a case study of tubulin. Biophys J (2002) 1.62
15N NMR spin relaxation dispersion study of the molecular crowding effects on protein folding under native conditions. J Am Chem Soc (2006) 1.60
Architecture of the high mobility group nucleosomal protein 2-nucleosome complex as revealed by methyl-based NMR. Proc Natl Acad Sci U S A (2011) 1.59
HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci U S A (2007) 1.58
Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol (2003) 1.58
ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem (2002) 1.56
Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J Exp Med (2006) 1.53
Binding specificity of multiprotein signaling complexes is determined by both cooperative interactions and affinity preferences. Biochemistry (2004) 1.52
Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol (2002) 1.46
Cooperative interactions at the SLP-76 complex are critical for actin polymerization. EMBO J (2010) 1.45
The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol (2002) 1.45
Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol (2006) 1.45
NMR structure of chaperone Chz1 complexed with histones H2A.Z-H2B. Nat Struct Mol Biol (2008) 1.40
Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263. J Immunol (2007) 1.39
Role for 53BP1 Tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling. J Biol Chem (2008) 1.38
Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. Cell Stem Cell (2007) 1.37
The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol Cell (2004) 1.36
Downstream E-box-mediated regulation of the human telomerase reverse transcriptase (hTERT) gene transcription: evidence for an endogenous mechanism of transcriptional repression. Mol Biol Cell (2002) 1.36
Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Res (2013) 1.33
ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol Cell Biol (2005) 1.31
Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions. J Am Chem Soc (2006) 1.31
Proteomic analysis of early melanosomes: identification of novel melanosomal proteins. J Proteome Res (2003) 1.31
Relationship between the native-state hydrogen exchange and folding pathways of a four-helix bundle protein. Biochemistry (2002) 1.29
Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure (2009) 1.28
Regulation of tyrosinase processing and trafficking by organellar pH and by proteasome activity. J Biol Chem (2003) 1.27
Regulation of the Wip1 phosphatase and its effects on the stress response. Front Biosci (Landmark Ed) (2012) 1.24
Substrate specificity of the human protein phosphatase 2Cdelta, Wip1. Biochemistry (2005) 1.23
Specific non-native hydrophobic interactions in a hidden folding intermediate: implications for protein folding. Biochemistry (2003) 1.22
The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. J Biol Chem (2002) 1.22
p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest (2013) 1.21
Sorting of Pmel17 to melanosomes through the plasma membrane by AP1 and AP2: evidence for the polarized nature of melanocytes. J Cell Sci (2006) 1.20
A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol (2002) 1.19
Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J (2004) 1.16
Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol (2004) 1.15
Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol (2010) 1.14
Detection of a hidden folding intermediate of the third domain of PDZ. J Mol Biol (2004) 1.13
A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J Immunol (2002) 1.13
The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression. J Biol Chem (2010) 1.13
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell (2006) 1.12
An exchange-free measure of 15N transverse relaxation: an NMR spectroscopy application to the study of a folding intermediate with pervasive chemical exchange. J Am Chem Soc (2007) 1.11
Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen. J Immunol (2002) 1.11
Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res (2002) 1.09
A model of voltage gating developed using the KvAP channel crystal structure. Biophys J (2004) 1.09
The folding pathway of T4 lysozyme: the high-resolution structure and folding of a hidden intermediate. J Mol Biol (2006) 1.08